脓毒性休克中的内皮通透性与止血:ProCESS 试验结果
本研究纳入ProCESS试验中605例推导队列和305例验证队列的脓毒性休克成人患者,比较三种复苏策略对循环内皮细胞通透性标志物(VEGF、sFLT-1、Ang-2)和止血标志物(vWF、TM、tPA)的影响,并分析标志物与60天院内死亡率的关系。结果显示,复苏策略与任何标志物水平均无显著关联;非存活者的Ang-2、sFLT-1、vWF、TM、tPA水平更高而VEGF更低(P均<.05)。基线sFLT-1对死亡率的区分度最高(推导队列AUC 0.74,验证队列0.70),与乳酸(AUC 0.74)和SOFA评分(AUC 0.73)相似;纳入所有时间点并校正年龄、癌症和Charlson合并症评分后,sFLT-1的校正AUC为0.80。
要点
- 在脓毒性休克成人中,三种复苏策略与内皮通透性及止血生物标志物水平均无显著关联。
- 非存活者Ang-2、sFLT-1、vWF、TM、tPA水平更高,VEGF水平更低(P均<.05)。
- 基线sFLT-1对60天院内死亡率的区分度:推导队列AUC 0.74,验证队列AUC 0.70。
- sFLT-1区分度与乳酸(AUC 0.74)和SOFA评分(AUC 0.73)相似。
- 纳入所有时间点并校正年龄、癌症和Charlson合并症评分后,sFLT-1的校正AUC为0.80。
适用人群与场景
- 美国31个急诊科收治的成人脓毒性休克患者,来自ProCESS试验参与者。
- 推导队列605例(来自1341例ProCESS参与者),验证队列305例。
研究设计与关键结果
- 研究类型:前瞻性生物标志物研究,嵌套于ProCESS试验,在美国31个急诊科开展。
- 样本量:推导队列605例,验证队列305例;推导队列死亡116例(19.2%),验证队列死亡52例(17.0%)。
- 干预:患者被随机分配至三种复苏策略之一,在入组时、6小时和24小时采集血样。
- 主要结果:复苏策略与任何生物标志物水平均无显著关联。
- 非存活者内皮通透性标志物(Ang-2、sFLT-1)和止血标志物(vWF、TM、tPA)更高,VEGF更低(P均<.05)。
- 基线sFLT-1对死亡率区分度最高:推导队列AUC 0.74,验证队列AUC 0.70;乳酸AUC 0.74,SOFA评分AUC 0.73。
- 纳入所有时间点并校正年龄、癌症和Charlson合并症评分后,sFLT-1的校正AUC为0.80。
证据类型、等级与局限
- 证据类型:前瞻性生物标志物研究,嵌套于随机对照试验ProCESS。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:不同复苏策略与脓毒症生物标志物谱无关,但内皮细胞通透性和止血标志物升高与死亡率增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We studied patients from the Protocolized Care in Early Septic Shock (ProCESS) trial to determine the effects of alternative resuscitation strategies on circulating markers of endothelial cell permeability and hemostasis and the association between biomarkers and mortality.
METHODS: This was a prospective study of biomarkers of endothelial cell permeability (vascular endothelial growth factor [VEGF], soluble fms-like tyrosine kinase 1 [sFLT-1], angiopoietin 2 [Ang-2]) and biomarkers of hemostasis (von Willebrand factor [vWF], thrombomodulin [TM], tissue plasminogen activator [tPA] in 605 of the 1,341 ProCESS participants in a derivation cohort and 305 participants in a validation cohort. Analyses assessed (1) the impact of varying resuscitation strategies on biomarker profiles and (2) the association of endothelial biomarkers with 60-day in-hospital mortality. The study was conducted in 31 US EDs in adult patients with septic shock. Patients were randomly assigned to one of three resuscitation strategies. Blood samples were collected at enrollment, at 6 h, and at 24 h.
RESULTS: There were 116 (19.2%) and 52 (17.0%) deaths in the derivation and validation cohorts, respectively. There was no significant association between treatment strategy and any biomarker levels. Permeability (Ang-2 and sFLT-1) and hemostasis (vWF, TM, tPA) biomarkers were higher and VEGF levels were lower in nonsurvivors (P < .05 for all). At baseline, sFLT-1 had the highest point estimate for mortality discrimination (derivation area under the curve [AUC], 0.74; validation, 0.70), similar to lactate (AUC, 0.74) and Sequential Organ Failure Assessment score (AUC, 0.73). In an analysis including all time points and adjusted for age, presence of cancer, and Charlson comorbidity score, the adjusted AUC for sFLT-1 was 0.80.
CONCLUSIONS: We found no relationship between different resuscitation strategies and biomarker profiles in sepsis, but we did find that elevated levels of endothelial cell biomarkers of permeability and hemostasis were associated with increased mortality.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00510835 and NCT00793442; URL: www.clinicaltrials.gov.
参考来源
- Hou PC, Filbin MR, Wang H, et al. Endothelial Permeability and Hemostasis in Septic Shock: Results From the ProCESS Trial. Chest. 2017. PMID: 28109962. doi:10.1016/j.chest.2017.01.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。